


Prophylactic **TRE**atment **O**f the du**C**tus **A**rteriosus in **P**reterm infants by **A**cetaminophen

Dear Investigators, dear National Hubs,
First of all, we wish you a **Happy New Year 2021!**
We look forward to a year full of achievements for the Treocapa study thanks to your collaboration and investment!

Regulatory Approval Status

- Both NCA/EC approvals received
- Pending either NCA or EC approval
- Pending both NCA and EC approvals



Site Opening Status:

11 sites are currently open for recruitment in France, Switzerland, Finland and Estonia and at least 9 additional sites will open by the end of February 2021.

Inclusions:

Phase II : 8 inclusions / Target : 30 patients
Phase III : 6 inclusions / Target : 794 patients

Treocapa Steering committee

Our third SC meeting was held on December 16 and 17, 2020 by web-conference. During this meeting, the creation of workgroups was discussed.

The aim of these workgroups is to maintain a collaborative work among SC members and support the development of ancillary studies.

SC members agreed on the setting up of 5 workgroups:

1	Pain, comfort and parent involvement	Leads: Ricardo Carbajal, Pierre Khun, Corinne Alberti
2	Neurology	Leads: Olivier Baud, Gorm Greisen, Mikko Hallman
3	Variations of practices	Leads : Pierre-Yves Ancel, Neil Marlow
4	Follow-up	Leads: Andrei Morgan, Pierre-Yves Ancel and Neil Marlow Additional members: Gorm Greisen, Mikko Hallman, Eugene Dempsey
5	Pharmacology	Leads: Naim Bouazza, Jean-Marc Treluyer, Mikko Hallman

Phase II :

Dose finding phase for 23-26 GA

2 cohorts of 3 patients have been completed and as part of the continual reassessment method, two interim statistical analysis were performed. Results of both analysis indicated that dose level 1 should be maintained to the next cohort (dose level 1 = 20 mg/kg loading dose then 7,5mg/kg/6 hours).

Treocapa Follow-Up amendment

The steering committee proposed an amendment to allow a follow-up. A protocol has been developed with a primary safety outcome that consists of evaluating survival without moderate or severe neurodevelopmental disability at 2 years corrected age.

A follow-up protocol proposal along with a funding request was submitted to c4c on Dec. 29, 2020. We expect to receive feedback from the Trial Commissioning Committee in the coming weeks.

TREOCAPA is a study co-developed with parents and their European representatives.

This study is funded by the c4c project. Find out more here : <https://conect4children.org/>